Does CVS Caremark Cover Wegovy? Coverage, Prior Authorization, and Costs

Wegovy (semaglutide) became one of the most sought-after prescription medications in America almost overnight. Approved by the FDA for chronic weight management in 2021, it has generated enormous demand — and equally enormous coverage questions. If your pharmacy benefits are managed by CVS Caremark, you are probably asking one thing: does CVS Caremark cover Wegovy? The short answer is that it depends on your specific plan, and the barriers are real. This guide explains how CVS Caremark works, why coverage is so plan-specific, and what to do next. (Free Market Healthcare is an independent education site and is not affiliated with CVS Caremark, CVS Health, or Novo Nordisk.)

First, What CVS Caremark Actually Is

An important distinction up front: CVS Caremark is a pharmacy benefit manager (PBM), not an insurance company. A PBM administers the prescription-drug portion of a health plan on behalf of the actual plan sponsor — your employer, your insurer, or a government program. CVS Caremark builds and manages formularies (covered-drug lists), negotiates with manufacturers, sets tiers, and runs prior-authorization and step-therapy programs. But the underlying decision about whether to cover a category like weight-loss drugs at all is usually made by the plan sponsor, not by the PBM. That is why two people who both “have CVS Caremark” can have completely different Wegovy coverage. For more on how these companies operate, see our overview of PBM services.

Does CVS Caremark Cover Wegovy?

CVS Caremark Wegovy coverage varies by plan. There is no single “yes” or “no,” because CVS Caremark administers pharmacy benefits for thousands of employers, insurers, and government programs, each with its own formulary and coverage rules.

Some plans include Wegovy on their formulary with prior-authorization requirements. Others exclude it entirely, particularly plans that classify anti-obesity medications as non-essential or “lifestyle” drugs. According to Kaiser Family Foundation research, a substantial share of employer-sponsored plans and Medicare Part D plans have historically excluded or restricted coverage of weight-loss medications — even as coverage for GLP-1 drugs used for diabetes is far more common. Exact figures shift year to year, so treat any single statistic as a snapshot rather than a permanent rule.

To check your specific coverage, log in to the CVS Caremark member portal (Caremark.com) and use the drug lookup tool, or call the member-services number printed on the back of your own prescription benefit card. Use the number on your card rather than one you find in a search result, because contact routing differs by plan. Our page on the CVS Caremark customer service number explains where to find the correct contact details for your plan.

Why Wegovy Coverage Is Complicated

Wegovy’s coverage landscape reflects broader tensions in how the U.S. healthcare system handles anti-obesity medications.

Cost. Wegovy’s list price has been well above $1,000 per month (list prices change and are often far higher than net negotiated prices). For plan sponsors, covering Wegovy for every eligible patient represents a potentially enormous expense. With a large share of American adults meeting criteria for obesity, the eligible population is vast, which is precisely why many sponsors hesitate.

Classification debates. Some plans treat obesity medications as “lifestyle” drugs and exclude them. Others recognize obesity as a chronic disease and cover treatment accordingly. Major medical organizations increasingly classify obesity as a treatable medical condition, but plan design has not caught up uniformly.

Prior authorization requirements. Even when Wegovy is on the formulary, most plans require prior authorization. Your prescriber must submit documentation showing you meet specific clinical criteria — typically a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, or high cholesterol. Some plans add step therapy, requiring you to try (and not succeed with) another therapy first.

How CVS Caremark’s Formulary Affects Wegovy (2025 Update)

Formulary placement is where a PBM’s decisions become very concrete, and there has been a notable recent change. In 2025, CVS Caremark’s standard commercial template formulary began preferring Wegovy over Zepbound (tirzepatide) among GLP-1 weight-management drugs, and Zepbound was removed from that standard commercial template effective July 1, 2025. In practice, that meant many members whose plans follow the standard template found Wegovy preferred and Zepbound no longer covered on the template — unless their plan chose a different or custom drug list.

Two big caveats apply. First, formularies change frequently — template lists are typically updated at least annually and sometimes mid-year — so what was true in mid-2025 may not describe your plan today. Second, your employer or insurer may not use the standard template at all; many large plans adopt custom formularies that cover different drugs or add their own restrictions. The only reliable answer is your plan’s current formulary, which you can check through the member portal. For background on how these lists work, see our explainer on the formulary. Which drug is right for you is a clinical decision for you and your prescriber, not something to choose based on formulary status alone.

CVS Caremark Wegovy Prior Authorization Criteria

When CVS Caremark–administered plans do cover Wegovy, prior-authorization criteria commonly include:

• BMI of 30 kg/m² or greater, or BMI of 27 kg/m² or greater with at least one weight-related condition
• Documentation that the patient has attempted lifestyle modifications (diet and exercise) without sufficient results
• Failure or intolerance of other weight-management therapies (some plans require step therapy)
• Ongoing monitoring by a healthcare provider
• Periodic reauthorization — often every 6 to 12 months — with documented progress

Your prescriber’s office submits the prior-authorization request to CVS Caremark. Processing commonly takes a few business days for standard requests, and expedited review is generally available when clinically warranted. Exact criteria and timelines vary by plan, so confirm the specifics for yours.

What Wegovy Costs Through CVS Caremark

If your plan covers Wegovy, your out-of-pocket cost depends on the formulary tier and your plan’s cost-sharing structure.

Many plans that cover Wegovy place it on a specialty or non-preferred brand tier (often Tier 4 or Tier 5), where coinsurance rates can range roughly from 25% to 50%. On a drug with a list price above $1,000, that could translate to a few hundred dollars or more per month out of pocket before any copay assistance. These are illustrative ranges only; your actual cost depends on your plan’s negotiated price and benefit design.

Novo Nordisk, Wegovy’s manufacturer, offers a savings program for eligible commercially insured patients that can reduce out-of-pocket cost for those who qualify. Such programs typically do not apply to government-funded insurance (Medicare, Medicaid, TRICARE) and carry their own eligibility rules and caps that change over time. Check the manufacturer’s current terms and ask your pharmacy about eligibility rather than assuming a specific dollar amount.

Understanding your plan’s tier structure is key to estimating costs. Plans administered by CVS Caremark may place the same drug on different tiers depending on the employer or insurer.

What If CVS Caremark Denies Wegovy Coverage?

A denial is not necessarily the final word. You have several options, best pursued with your prescriber.

Appeal the denial. Your prescriber can submit an appeal with additional clinical documentation. If Wegovy is excluded from the formulary entirely, a formulary-exception request may be appropriate — your prescriber must argue that no covered alternative is clinically suitable for you.

Discuss diabetes vs. weight-loss indications. Ozempic contains the same active ingredient (semaglutide) but is FDA-approved for type 2 diabetes, not weight loss. If you have type 2 diabetes, your prescriber may determine Ozempic is appropriate, and some plans cover it more readily. Prescribing any drug outside its approved indication is a clinical decision for your prescriber and may not be covered.

Ask about other GLP-1 options. Depending on your plan’s current formulary, medications such as Saxenda (liraglutide) or Zepbound (tirzepatide) may have different placement. Ask your prescriber whether an alternative is medically appropriate for you.

Check for employer plan changes. Some employers add or expand anti-obesity coverage in response to employee demand; others narrow it to control cost. During open enrollment, ask your HR department whether Wegovy or similar medications will be covered in the upcoming plan year.

Use manufacturer programs. Novo Nordisk’s patient-assistance programs may help eligible patients who lack adequate coverage. Review the manufacturer’s current terms or ask your prescriber’s office for details.

Medicare Part D and Wegovy

By statute, Medicare Part D has generally been prohibited from covering drugs used solely for weight loss. This has been shifting at the margins — for example, coverage may apply when a GLP-1 is approved for a condition Medicare already covers (such as reducing cardiovascular risk in certain patients), rather than for weight loss alone. Policy in this area continues to evolve.

If you are a Medicare beneficiary interested in Wegovy, check the latest guidance on Medicare.gov or see our Medicare formulary guide for how to check drug coverage. For a deeper look, our article on does Medicare cover Wegovy provides more detail.

The Bigger Picture: PBMs and Weight-Loss Drug Coverage

CVS Caremark’s formulary decisions about Wegovy reflect a broader industry challenge. PBMs must balance the clinical evidence supporting anti-obesity medications against the financial impact of covering them for millions of eligible patients. KFF analyses have estimated that broad GLP-1 coverage at list prices could add very large sums to national drug spending, which helps explain why plan sponsors and PBMs impose so many guardrails.

This tension is playing out across all major PBMs, not just CVS Caremark; Express Scripts and OptumRx face the same debates. For context on how PBMs make these decisions, see our article on PBM services.

Frequently Asked Questions

Does CVS Caremark cover Wegovy?

It depends on your specific plan. Some CVS Caremark–administered plans cover Wegovy with prior authorization; others exclude weight-loss drugs entirely. Check your plan’s formulary through the member portal at Caremark.com or by calling the number on your member ID card.

Is CVS Caremark my insurance company?

No. CVS Caremark is a pharmacy benefit manager that administers the drug portion of a plan for your employer, insurer, or government program. Your insurer or plan sponsor typically decides whether categories like weight-loss drugs are covered at all.

How much does Wegovy cost with CVS Caremark?

If covered, it is often on a specialty or non-preferred tier with coinsurance that can run roughly 25% to 50%, which can mean several hundred dollars a month before any manufacturer copay assistance. Costs vary significantly by plan.

Did CVS Caremark stop covering Zepbound?

On its standard commercial template formulary, CVS Caremark removed Zepbound effective July 1, 2025, and preferred Wegovy among GLP-1 weight-management drugs. However, formularies change and many plans use custom lists, so verify your own plan’s current coverage before assuming either drug is or isn’t covered.

How do I find the right phone number to check my coverage?

Use the member-services number printed on the back of your own prescription benefit or ID card, or sign in at Caremark.com. Contact routing varies by plan, so the number on your card is the reliable one — avoid dialing a number pulled from a general search result.

What if I cannot afford Wegovy even with insurance?

Check Novo Nordisk’s current savings program for eligible commercially insured patients, and ask about patient-assistance foundations. Your specialty pharmacy care team can also help search for financial-assistance options.

Next Steps for Wegovy Coverage

Navigating CVS Caremark Wegovy coverage comes down to a few steps: understand that CVS Caremark is the PBM (not your insurer), check your specific plan’s current formulary, learn the prior-authorization and step-therapy requirements, and be prepared to appeal or explore alternatives if coverage is denied. Start with your member portal or the number on your ID card, work closely with your prescribing clinician, and do not overlook manufacturer assistance programs that can substantially reduce costs. For a broader view of healthcare coverage in America, visit our healthcare policy guide.

Sources

• CVS Caremark / CVS Health — public formulary and template drug-list communications, including 2025 standard commercial template changes affecting GLP-1 weight-management drugs (Wegovy preferred; Zepbound removed from the standard commercial template effective July 1, 2025). Verify against your plan’s current formulary.
• Kaiser Family Foundation (KFF) — research on GLP-1 / anti-obesity medication coverage by employers and Medicare, and the potential budget impact of broad coverage
• Novo Nordisk — Wegovy prescribing information and manufacturer savings / patient-assistance program terms (eligibility limited to certain commercially insured patients; excludes government programs)
• U.S. Food and Drug Administration (FDA) — Wegovy (semaglutide) approval for chronic weight management (2021)